News and Events

Hoosier Cancer Research Network (HCRN) launched an updated website today with new features and a modernized design. The new website, developed in collaboration with THE PLAID AGENCY, provides ease of access to our most-visited content: our clinical trials and our network, as well a drop-down menu that allows site visitors to learn more about HCRN’s services, history, and staff. The new website features a newly designed careers page that offers an informative look at HCRN’s workplace culture, benefits, and open...

Researchers participating in the Hoosier Cancer Research Network GU16-260 study have published a correlative analysis in Cancer Discovery. The analysis, led by David A. Braun, MD, PhD, of Yale Cancer Center; Catherine J. Wu, MD, of the Dana-Farber Cancer Institute; and Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, found that the presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Congratulations to all co-authors and study teams...

Hoosier Cancer Research Network (HCRN) is set to participate in ASCO GU 2025 in San Francisco from February 13-15, 2025, with HCRN-GU16-243 being presented as a Rapid Oral Abstract, and several other studies as poster presentations.

A Hoosier Cancer Research Network abstract, HCRN-LUN21-497, titled, “Results from a phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer,” was presented at SITC 2024 by Jeffrey Clarke, MD, of Duke University.

HCRN-GI23-643, titled, “Randomized Trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer,” will be presented as a Trials in Progress poster at the American Society of Clinical Oncology® (ASCO) Gastrointestinal Cancers Symposium 2025 in San Francisco. This study is led by Ibrahim Sahin, MD, of UPMC Hillman Cancer Center.

A correlative study related to the Hoosier Cancer Research Network (HCRN) clinical trial, HCRN-GU16-243, titled, “A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study,” was presented at SUO 2024 by Noah Hahn, MD, of Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center.

A Hoosier Cancer Research Network (HCRN) study, HCRN-LUN18-335, led by Xiuning Le, MD, PhD, of the University of Texas MD Anderson Cancer Center, was published in the Journal of Clinical Oncology on October 8, 2024. The article is titled, “A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial).” Congratulations to all co-authors and study teams whose hard work led to this publication!

Hoosier Cancer Research Network congratulates Rita Assi, MD, on her election as the President-Elect of the Indiana Oncology Society 2024-2026 Board of Directors. Dr. Assi is a board member of HCRN and is assistant professor of clinical medicine at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Hoosier Cancer Research Network (HCRN) recently joined two of our visionary founders, Patrick J. Loehrer, MD, and William B. Fisher, MD, as they shared stories spanning their 40 years of involvement with HCRN, formerly known as Hoosier Oncology Group, or affectionately, the “HOG.”

A Hoosier Cancer Research Network trial, HCRN-LUN18-357, titled “P1.08D.03 Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-Small Cell Lung Cancer (NSCLC)” has been accepted as a poster presentation and will be presented at the World Conference on Lung Cancer Meeting on September 8, 2024 from 12:00 pm-2:00 pm.